Advances in Tracking Anticancer Drugs to Their Targeted Site: A Review
DOI:
https://doi.org/10.32947/ajps.v25i5.1299Keywords:
theranostic, magnetic resonance imaging (MRI), positron emission tomography (PET), fluorescence imaging, artificial intelligence and machine learning in oncologyAbstract
The targeted delivery of chemotherapy drugs to their specific locations in a tumor is a cornerstone of current oncology for high therapeutic efficacy and reduced systemic toxicity. Recent breakthroughs in nanotechnology, molecular and imaging modalities have revolutionized the field of targeted delivery and tracking technology. With these new advances, the real-time tracking of drug routes and increased accuracy in tumor localization have become a reality.
This review has discussed advanced targeting approaches, such as passive and active targeting, multifunctional theranostics and stimuli-responsive platforms to describe their mechanism, clinical utility and challenges. In addition, tracking modalities such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have played a key role in noninvasive tracking and have been discussed in detail. Challenges such as immune clearance, tumor heterogeneity and translational barriers have been discussed, and new avenues through artificial intelligence, biomarker-guided approaches and therapeutic platforms have been explored in detail. Emerging studies have also shed new light on targeted oncology, combining biomarker discovery and new therapeutic platforms with individualized patient requirements. A thorough analysis reveals an interdisciplinary obstacle in developing targeted delivery technology and shaping future cancer therapy.
References
1- Huang X, He T, Liang X, Xiang Z, Liu C, Zhou S, Luo R, Bai L, Kou X, Li X, Wu R. Advances and applications of nanoparticles in cancer therapy. MedComm–Oncology. 2024 Mar;3(1):e67.
2- Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nature Reviews Materials. 2021 Sep;6(9):766-83.
3- Alaayedi MH, Maraie NK. Effect of Pluronic F127 Concentration on Gelling Temperature and other Parameters of Lomustine Mucoadhesive In-Situ Gel. Iraqi Journal of Pharmaceutical Sciences. 2024 Sep 15;33(3):63-71.
4- Li G, Wang C, Jin B, Sun T, Sun K, Wang S, Fan Z. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discovery. 2024 Nov 11;10(1):466.
5- Chaudhari R, Patel V, Kumar A. Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies. Nanoscale Advances. 2024.
6- Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduction and Targeted Therapy. 2024 Aug 12;9(1):200.
7- Hussein HA, Maraie NK. Highlights on polymeric micelles as versatile nanocarriers for drug transporting. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021;21(2):21-30.
8- Dakhil IA, Maraie NK. Variables Affecting the Preparation and Characterization of Axitinib as Oral Niosmoes. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2024 Sep 15;33(3):115-27.
9- Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.
10- Selepe CT, Dhlamini KS, Tshweu L, Moralo M, Kwezi L, Ray SS, Ramalapa B. Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities. Nano Select. 2024 May;5(5):2300191.
11- Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S. The role of biomarkers in personalized immunotherapy. Biomarker Research. 2022 May 18;10(1):32.
12- Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life sciences. 2024 Jul 9:122899.
13- Sahu RK, editor. Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications. Bentham Science Publishers; 2023 Sep 2.
14- Vangijzegem T, Lecomte V, Ternad I, Van Leuven L, Muller RN, Stanicki D, Laurent S. Superparamagnetic iron oxide nanoparticles (SPION): from fundamentals to state-of-the-art innovative applications for cancer therapy. Pharmaceutics. 2023 Jan 10;15(1):236.
15- Jayapriya P, Pardhi E, Vasave R, Guru SK, Madan J, Mehra NK. A review on stimuli-pH responsive liposomal formulation in cancer therapy. Journal of Drug Delivery Science and Technology. 2023 Nov 15:105172.
16- Tiryaki ME, Doğangün F, Dayan CB, Wrede P, Sitti M. MRI-powered Magnetic Miniature Capsule Robot with HIFU-controlled On-demand Drug Delivery. In2023 IEEE International Conference on Robotics and Automation (ICRA) 2023 May 29 (pp. 5420-5425). IEEE.
17- Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. Journal of biomedical science. 2022 Oct 17;29(1):83.
18- Haumann R, Videira JC, Kaspers GJ, van Vuurden DG, Hulleman E. Overview of current drug delivery methods across the blood–brain barrier for the treatment of primary brain tumors. CNS drugs. 2020 Nov;34(11):1121-31.
19- Khudhur AQ, Maraie NK, Raauf AM. Highlight on lipids and its use for covalent and non-covalent conjugations. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2020 Sep 1;20(3):1-3.
20- Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nature communications. 2018 Apr 12;9(1):1410.
21- Li P, Wang D, Hu J, Yang X. The role of imaging in targeted delivery of nanomedicine for cancer therapy. Advanced Drug Delivery Reviews. 2022 Oct 1;189:114447.
22- Lapusan R, Borlan R, Focsan M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. Nanoscale Advances. 2024.
23- Singh P, Pandit S, Balusamy SR, Madhusudanan M, Singh H, Amsath Haseef HM, Mijakovic I. Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications. Advanced Healthcare Materials. 2024:2403059.
24- Jørgensen SH, Bøgh N, Hansen ES, Væggemose M, Wiggers H, Laustsen C. Hyperpolarized MRI–An update and future perspectives. InSeminars in Nuclear Medicine 2022 May 1 (Vol. 52, No. 3, pp. 374-381). WB Saunders.
25- Radaram B, Glazer SE, Yang P, Li CW, Hung MC, Gammon ST, Alauddin M, Piwnica-Worms D. Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET. ACS omega. 2023 May 4;8(19):17181-94.
26- Zheng KH, Kroon J, Schoormans J, Gurney-Champion O, Meijer SL, Gisbertz SS, Hulshof MC, Vugts DJ, van Dongen GA, Coolen BF, Verberne HJ. 89Zr-labeled high-density lipoprotein nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer. Journal of Nuclear Medicine. 2022 Dec 1;63(12):1880-6.
27- Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. Journal of Nanobiotechnology. 2024 Nov 22;22(1):728.
28- Wang T, Chen Y, Wang B, Wu M. Recent progress of second near-infrared (NIR-II) fluorescence microscopy in bioimaging. Frontiers in Physiology. 2023 Feb 21;14:1126805.
29- Xin Y, Yin M, Zhao L, Meng F, Luo L. Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer biology & medicine. 2017 Aug;14(3):228.
30- Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging?. InSeminars in nuclear medicine 2008 May 1 (Vol. 38, No. 3, pp. 199-208). WB Saunders.
31- Wei X, Zhao H, Huang G, Liu J, He W, Huang Q. ES-MION-based dual-modality PET/MRI probes for acidic tumor microenvironment imaging. ACS omega. 2022 Jan 18;7(4):3442-51.
32- Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, Kuwert T, La Fougère C, Mariani G, Massalha S, Paez D. Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence. European journal of nuclear medicine and molecular imaging. 2019 Sep 1;46:1990-2012.
33- Meng B, Song J, Liu L, Chen L, Chen X. Added value of hybrid SPECT with CT imaging for predicting poor therapeutic efficacy of 89Sr in patients with bone metastasis. Scientific Reports. 2020 Dec 3;10(1):21207.
34- Xia Y, Duan S, Han C, Jing C, Xiao Z, Li C. Hypoxia-responsive nanomaterials for tumor imaging and therapy. Frontiers in Oncology. 2022 Dec 15;12:1089446.
35- Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020 Apr 20;10(4):787.
36- Verhoef JJ, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug delivery and translational research. 2013 Dec;3:499-503.
37- Qiu S, Zhu F, Tong L. Application of targeted drug delivery by cell membrane-based biomimetic nanoparticles for inflammatory diseases and cancers. European Journal of Medical Research. 2024 Oct 30;29(1):523.
38- Wang S, Li B, Zhang F. Molecular fluorophores for deep-tissue bioimaging. ACS central science. 2020 Jul 23;6(8):1302-16.
39- Young H, He Y, Joo B, Ferguson S, Demko A, Butterfield SK, Lowe J, Mjema NF, Sheth V, Whitehead L, Ruiz-Echevarria MJ. Toward the Scalable, Rapid, Reproducible, and Cost-Effective Synthesis of Personalized Nanomedicines at the Point of Care. Nano Letters. 2024 Jan 11;24(3):920-8.
40- Singh AV, Bhardwaj P, Upadhyay AK, Pagani A, Upadhyay J, Bhadra J, Tisato V, Thakur M, Gemmati D, Mishra R, Zamboni P. Navigating regulatory challenges in molecularly tailored nanomedicine.
41- Mahdi ZH, Suhail A, Maraie NK, Kathem HS. Variables Affecting In-Vitro Evaluation of Loxoprofen Sodium Topical Emulgel. Iraqi Journal of Pharmaceutical Sciences. 2024 Jun 29;33(2):92-100.
42- Ilan Y. Next-generation personalized medicine: implementation of variability patterns for overcoming drug resistance in chronic diseases. Journal of Personalized Medicine. 2022 Aug 10;12(8):1303.
43- Su J, Yang L, Sun Z, Zhan X. Personalized drug therapy: innovative concept guided with proteoformics. Molecular & Cellular Proteomics. 2024 Mar 1;23(3).
44- Hristova-Panusheva K, Xenodochidis C, Georgieva M, Krasteva N. Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. Pharmaceuticals. 2024 May 24;17(6):677.
45- National Institutes of H. AI tool predicts response to cancer therapy. 2024.
46- Bhandari A. Revolutionizing Radiology With Artificial Intelligence. Cureus. 2024 Oct 29;16(10).
47- Lapusan R, Borlan R, Focsan M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. Nanoscale Advances. 2024.
48- Jo SD, Ku SH, Won YY, Kim SH, Kwon IC. Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy. Theranostics. 2016;6(9):1362.
49- Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances. 2020 Nov 18;6(47):eabc9450.
50- Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances. 2020 Nov 18;6(47):eabc9450.
51- Steinberg E, Friedman R, Goldstein Y, Friedman N, Beharier O, Demma JA, Zamir G, Hubert A, Benny O. A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine. Communications Biology. 2023 Nov 13;6(1):1157.
52- Monteiro MV, Zhang YS, Gaspar VM, Mano JF. 3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models. Trends in biotechnology. 2022 Apr 1;40(4):432-47.
53- Malik MM, Alqahtani MM, Hadadi I, Kanbayti I, Alawaji Z, Aloufi BA. Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications. Diagnostics. 2024 Nov 3;14(21):2459.
54- Zurynski Y, Herkes-Deane J, Holt J, McPherson E, Lamprell G, Dammery G, Meulenbroeks I, Halim N, Braithwaite J. How can the healthcare system deliver sustainable performance? A scoping review. BMJ open. 2022 May 1;12(5):e059207.
55- Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024 Nov 30;12(12):2750.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ali N. Wannas, Monther Faisal Mahdi, Nidhal K. Maraie
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
